Sabatine, Marc S.

244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

RAZ, I., WIVIOTT, S. D., YANUV, I., ROZENBERG, A., ZELNIKER, T. A., CAHN, A., HEERSPINK, H. L., DWYER, J. P., GOODRICH, E., BHATT, D. L., et al. (2019) · Diabetes

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 15

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab

Korthauer, L. E., Giugliano, R. P., Guo, J., Sabatine, M. S., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C. T., Mach, F., et al. (2022) · PLOS ONE

Lipoproteins and Cardiovascular HealthAlzheimer's disease research and treatments

Cited by 11

Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial

Kang, Y. M., Giugliano, R. P., Ran, X., Deedwania, P., De Ferrari, G. M., George, J. T., Gouni-Berthold, I., Paiva da Silva Lima, G., Handelsman, Y., Lewis, B. S., et al. (2025) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 9